|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||191.60 - 196.03|
|52 Week Range||150.38 - 196.03|
|PE Ratio (TTM)||17.34|
|Forward Dividend & Yield||5.28 (2.79%)|
|1y Target Est||N/A|
Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,
Nektar Therapeutics (NKTR) has entered into a number of licensing and collaboration agreements for research, development, and commercialization with various healthcare companies, including Eli Lilly (LLY), AstraZeneca (AZN), and Amgen (AMGN). Under these agreements, Nektar is entitled to receive license fees, milestone payments, royalties, and payments for manufacturing and supplying Nektar’s proprietary PEGylation materials.
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Amgen, Inc. (NASDAQ: AMGN ) is likely to helped by both fundamental catalysts and the positive impact of the new U.S. tax law, an analyst said. The Analyst Argus analyst David Toung upgraded Amgen from ...
The stock market traded at session highs Monday afternoon after congressional leaders said they've reached an accord to end the federal government shutdown.
A handful of stocks broke out. Some breakouts came in strong volume, but others poked above a buy point in weak volume.
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
The Zacks Analyst Blog Highlights: UnitedHealth, Amgen, United Technologies, CSX and General Dynamics
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis